Long‐Term Efavirenz Autoinduction and Its Effect on Plasma Exposure in HIV Patients

[1]  Zeruesenay Desta,et al.  Efavirenz Primary and Secondary Metabolism In Vitro and In Vivo: Identification of Novel Metabolic Pathways and Cytochrome P450 2A6 as the Principal Catalyst of Efavirenz 7-Hydroxylation , 2010, Drug Metabolism and Disposition.

[2]  V. Preedy,et al.  Prospective Cohort Study , 2010 .

[3]  L. Milani,et al.  A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans. , 2009, British journal of clinical pharmacology.

[4]  D. Grasela,et al.  Model-Based Approach To Characterize Efavirenz Autoinduction and Concurrent Enzyme Induction with Carbamazepine , 2009, Antimicrobial Agents and Chemotherapy.

[5]  M. J. García,et al.  Influence of the Cytochrome P450 2B6 Genotype on Population Pharmacokinetics of Efavirenz in Human Immunodeficiency Virus Patients , 2009, Antimicrobial Agents and Chemotherapy.

[6]  S. Staszewski,et al.  Factors associated with viral rebound among highly treatment‐experienced HIV‐positive patients who have achieved viral suppression , 2009, HIV medicine.

[7]  W. Haefeli,et al.  Induction of multiple drug transporters by efavirenz. , 2009, Journal of pharmacological sciences.

[8]  Jingdong Xie,et al.  Pharmacokinetic Interaction Between Efavirenz and Carbamazepine After Multiple‐Dose Administration in Healthy Subjects , 2008, Journal of clinical pharmacology.

[9]  Prosper Chonzi,et al.  High prevalence of the CYP2B6 516G→T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe , 2008, European Journal of Clinical Pharmacology.

[10]  W. Haefeli,et al.  Electrospray tandem mass spectroscopic characterisation of 18 antiretroviral drugs and simultaneous quantification of 12 antiretrovirals in plasma. , 2007, Rapid communications in mass spectrometry : RCM.

[11]  Hongbing Wang,et al.  Relative Activation of Human Pregnane X Receptor versus Constitutive Androstane Receptor Defines Distinct Classes of CYP2B6 and CYP3A4 Inducers , 2007, Journal of Pharmacology and Experimental Therapeutics.

[12]  K. Tashima,et al.  Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  M. Hirsch,et al.  Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study. , 2005, The Journal of infectious diseases.

[14]  S. Khoo,et al.  Intracellular and plasma pharmacokinetics of efavirenz in HIV-infected individuals. , 2005, The Journal of antimicrobial chemotherapy.

[15]  T. Puthanakit,et al.  Efficacy of highly active antiretroviral therapy in HIV-infected children participating in Thailand's National Access to Antiretroviral Program. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  A. Y. Lu,et al.  METABOLISM-BASED DRUG-DRUG INTERACTIONS: WHAT DETERMINES INDIVIDUAL VARIABILITY IN CYTOCHROME P450 INDUCTION? , 2005, Drug Metabolism and Disposition.

[17]  F. Maggiolo,et al.  Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  Catia Marzolini,et al.  Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study , 2004, AIDS.

[19]  A. Sönnerborg,et al.  Efavirenz Plasma Concentrations in HIV-Infected Patients: Inter- and Intraindividual Variability and Clinical Effects , 2004, Therapeutic drug monitoring.

[20]  D. Greenblatt,et al.  Differential Modulation of P-Glycoprotein Expression and Activity by Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors in Cell Culture , 2002, Pharmaceutical Research.

[21]  J. Schubert,et al.  No influence of the P-glycoprotein genotype (MDR1 C3435T) on plasma levels of lopinavir and efavirenz during antiretroviral treatment. , 2003, European journal of medical research.

[22]  A. Mocroft,et al.  Virological rebound after suppression on highly active antiretroviral therapy , 2003, AIDS.

[23]  S. Khoo,et al.  The effects of protease inhibitors and nonnucleoside reverse transcriptase inhibitors on p-glycoprotein expression in peripheral blood mononuclear cells in vitro. , 2003, Journal of acquired immune deficiency syndromes.

[24]  C. Bellodi,et al.  MDR1 C3435T genetic polymorphism does not influence the response to antiretroviral therapy in drug-naive HIV-positive patients , 2003, AIDS.

[25]  David A. Flockhart,et al.  The Cytochrome P450 2B6 (CYP2B6) Is the Main Catalyst of Efavirenz Primary and Secondary Metabolism: Implication for HIV/AIDS Therapy and Utility of Efavirenz as a Substrate Marker of CYP2B6 Catalytic Activity , 2003, Journal of Pharmacology and Experimental Therapeutics.

[26]  Jacques Fellay,et al.  Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection , 2003, Clinical pharmacology and therapeutics.

[27]  J. Barrett,et al.  Population pharmacokinetic meta-analysis with efavirenz. , 2002, International journal of clinical pharmacology and therapeutics.

[28]  H. Klinker,et al.  Efavirenz plasma levels for the prediction of treatment failure in heavily pretreated HIV-1 infected patients. , 2002, European journal of medical research.

[29]  P. Watkins,et al.  Hepatic but not intestinal CYP3A4 displays dose‐dependent induction by efavirenz in humans , 2002, Clinical pharmacology and therapeutics.

[30]  Jacques Fellay,et al.  Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study , 2002, The Lancet.

[31]  V. Soriano,et al.  Higher efavirenz plasma levels correlate with development of insomnia. , 2001, Journal of acquired immune deficiency syndromes.

[32]  Brendan Larder,et al.  Genotypic Correlates of Phenotypic Resistance to Efavirenz in Virus Isolates from Patients Failing Nonnucleoside Reverse Transcriptase Inhibitor Therapy , 2001, Journal of Virology.

[33]  A. Telenti,et al.  Efavirenz Plasma Levels Can Predict Treatment Failure and Central Nervous System Side Effects in Hiv-1-infected Patients , 2022 .

[34]  Patrick F. Smith,et al.  Clinical Pharmacokinetics of Non-Nucleoside Reverse Transcriptase Inhibitors , 2001, Clinical pharmacokinetics.

[35]  A. Mocroft,et al.  Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study. , 2000, Archives of internal medicine.

[36]  A. Telenti,et al.  Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study , 1999, The Lancet.

[37]  D. Roden,et al.  The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. , 1998, The Journal of clinical investigation.

[38]  A. Shepherd,et al.  Reduced induction of drug metabolism in the elderly. , 1978, Age and ageing.